{"id":"cd137","name":"CD137 (4-1BB, TNFRSF9)","symbol":"TNFRSF9","route":"/targets/cd137/","asOf":"2026-09-22","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11924","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000049249","uniprot":"https://www.uniprot.org/uniprotkb/Q07011/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q07011","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3712857","open-targets":"https://platform.opentargets.org/target/ENSG00000049249","civic":"https://civicdb.org/genes/3604/summary","oncokb":"https://www.oncokb.org/gene/TNFRSF9","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TNFRSF9","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=TNFRSF9","depmap":"https://depmap.org/portal/gene/TNFRSF9?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000049249-TNFRSF9","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3604","omim":"https://www.omim.org/entry/602250"}],"products":[{"id":"acasunlimab","name":"Acasunlimab","status":"phase-3","modality":"bispecific antibody","route":"/drugs/acasunlimab/"},{"id":"cinrebafusp-alfa","name":"Cinrebafusp alfa","status":"phase-2","modality":"fusion protein","route":"/drugs/cinrebafusp-alfa/"}],"trials":[{"id":"nct06635824","name":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","nct":"NCT06635824","phase":"3","status":"active"},{"id":"nct05190445","name":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","nct":"NCT05190445","phase":"2","status":"active"},{"id":"nct05117242","name":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","nct":"NCT05117242","phase":"2","status":"withdrawn"}],"pathways":[],"companies":["genmab","pieris-pharmaceuticals"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}